Arca
Skip to content
Tools
Tools

Pruritus

Drug research and approvals for pruritus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 59 studies of pruritus are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 7 approved and 2 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 59
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 7
  • EU medicines: 4

Recruiting now

Newest posted first, of 59 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 38

Phase 3 12

Phase 2 12 of 19

Phase 1 or earlier 10

How its trials ended

304 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 68 whose ending is known, 49% met their primary endpoint, 7% missed it and 44% stopped early.

  • Completed, result not reported16053%
  • Ongoing4414%
  • Met its primary endpoint3311%
  • Status unknown3211%
  • Stopped: other or unclear176%
  • Missed its primary endpoint52%
  • Stopped: enrollment or feasibility52%
  • Stopped: lack of efficacy31%
  • Stopped: sponsor or business decision31%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 5, 2025Randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of maralixibat in the treatment of participants with cholestatic…MaralixibatMirum PharmaceuticalsOngoing
Aug 3, 2022Randomized, double-blind, placebo-controlled study to evaluate the effects of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis or…EP547Escient Pharmceuticals IncClosed

FDA orphan designations

Approved first, then open designations, newest first
Mar 17, 2026LynavoyTreatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patientsIntercept Pharmaceuticals, Inc. (A wholly owned subsidiary of Alfasigma S.p.A.)Approved
Jul 24, 2024LivmarliTreatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)Mirum Pharmaceuticals, Inc.Approved
Mar 13, 2024LivmarliTreatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC)Mirum Pharmaceuticals, Inc.Approved
Jun 13, 2023BylvayTreatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS)Ipsen Biopharmaceuticals, Inc.Approved
Mar 13, 2023LivmarliTreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and olderMirum Pharmaceuticals, Inc.Approved
Sep 29, 2021LivmarliTreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and olderMirum Pharmaceuticals, Inc.Approved
Jul 20, 2021BylvayTreatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use:…Ipsen Biopharmaceuticals, Inc.Approved
Nov 23, 2010NaloxoneTopical treatment of pruritus associated with mycosis fungoidesElorac, Inc.Designated
Sep 3, 2004Buffered Ursodeoxycholic AcidTreatment of pruritus in patients with Alagille SyndromeDigestive Care, Inc.Designated

Medicines authorised in the EU

Newest first
Oct 22, 2026LynavoyLinerixibat · orphanGlaxoSmithKline Trading Services LimitedEMA ↗
Sep 19, 2024KayfandaOdevixibatIpsen PharmaEMA ↗
Dec 9, 2022LivmarliMaralixibat chloride · orphanMirum Pharmaceuticals International B.V.EMA ↗
Apr 25, 2022KapruviaDifelikefalinVifor Fresenius Medical Care Renal Pharma FranceEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.